Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06512376

Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort

We took hereditary cerebral small vessel disease (hCSVD) patients as our main subjects, aiming to establish a platform for a comprehensive evaluation and long-term follow-up. Deeply explore the pathophysiological mechanism of hCSVD, which may render the theoretical basis for the treatment and management of hCSVD.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Beijing Tiantan Hospital

Beijing, 100050, China

About this study

Cerebral Small Vessel Disease is a series of clinical, imaging, and pathological syndromes caused by a variety of risk factors affecting cerebral arterioles, arterioles, capillaries, and venules, accounting for 20% of stroke and 45% of dementia.

Although the incidence rate of hereditary small cerebral vascular disease is low, because of its early onset, high disability rate, and lack of effective treatment, it also brings a heavy burden to the patients and their families. Therefore, it is important to study the pathogenic gene, pathogenesis, clinical characteristics, and imaging manifestations of hereditary cerebrovascular disease to provide a theoretical basis for the treatment and prevention of hereditary cerebrovascular disease in the future.

This multi-center, prospective, continuous, registry study, runs from 2022 to 2027. The study is expected to recruit 100 subjects, according to the sample size design of the registry study.

We recruited patients with the hereditary cerebral small-vessel disease (hCSVD) intending to establish a platform for a comprehensive assessment and long-term follow-up by collecting genetics, imaging, and clinical symptoms of the primary disease and its relatives. With long-term follow-up of the development and prognosis of imaging and clinical symptoms combined with genetics, we will work on the correlation between genes and phenotype and deeply explore the pathophysiological mechanism of hCSVD, which may render the theoretical basis for the treatment and management of hCSVD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All ages, male or female
  • Carriers of the pathogenic genes mutation (mutation with unknown clinical significance/ suspected pathogenic mutation/ pathogenic mutation) of hCSVD confirmed by the gene tests, including but not limited to NOTCH3, HTPA1, CTSA, GLA, TREX1, COL4A1/2, or highly-suspected hCSVD2
  • CSVD related abnormalities on brain MRI, any 1 or more of:
  • White matter hyperintensities, Fazekas score3 ≥1
  • ≥1 newly-occurred lacunar infarcts
  • ≥1 old lacunar infarcts
  • ≥3 cerebral microbleeds
  • Informed consent signed

Exclusion criteria

  • Diagnosis of mental disorders according to DSM-V and unable to be compliant to the research
  • Patients with life expectancy less than one year due to any advanced disease, e.g., malignant tumor
  • Patients unable to return for follow-up visits due to some reasons

Treatment and study plan

Primary outcomes

  1. The epidemiological features

    Time frame: at baseline

    Any epidemiological informations

  2. The clinical features

    Time frame: 5 years

    Clinical symptoms and physical examination

  3. The radiography features

    Time frame: at baseline

    Neuroimaging markers collected by MRI

  4. A novel pathogenic gene for hereditary cerebrovascular disease in the Chinese population

    Time frame: at baseline

    Genetic testing with the blood sample

Secondary outcomes

  1. Etiology and pathogenesis

    Time frame: at baseline

    This study will collect etiology and pathogenesis information among participants.

  2. Long-term changes of radiography features

    Time frame: 5 years

    Neuroimaging markers collected by MRI

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Registry information

Official study title

Hereditary Cerebral Small Vessel Diseases Registry-Trial Ready Cohort (HCSVD-TRC)

Acronym: HCSVD-TRC

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jul 22, 2024
Registry last updated
Jul 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.